AUPH has two very large market opportunities for its voclosporin drug.
The charts of REGN could use more than media coverage.
BMY's announced acquisition of MyoKardia for $13B comes less than a year after its purchase of Celgene.
Stocks of companies that have Covid-19 vaccine candidates have boomed while those in the treatment space have not.
The charts and indicators of SGEN are looking healthy.
Shares of Heron Therapeutics and Myovant Sciences have taken hits but both companies still show promise.
This is the type of chart that will grab the attention of momentum traders.
Let's review the charts and indicators.
I would consider SNY a hold at this point in time.
I see no reason to flee this name, therefore, I am not.